NeoGenomics has commercially launched the c-MET Companion Diagnostic (CDx) for use in non-small cell lung cancer (NSCLC), offering a 48-hour turnaround for oncologists and pathologists.
This new immunohistochemistry (IHC) assay is designed to detect the overexpression of c-Met (mesenchymal-epithelial transition factor) protein, which is found in up to half of individuals with advanced NSCLC.
The c-MET CDx for NSCLC assay is intended to detect individuals who may benefit from targeted therapies such as AbbVie鈥檚 Emrelis (telisotuzumab vedotin-tllv), which was recently approved by the US Food and Drug Administration (FDA).
Developed in line with the regulator鈥檚 guidance, the assay is said to be validated for use with MET-targeted treatments while enabling timely clinical decision-making.
NeoGenomics noted that the assay complements the company鈥檚 PanTracer portfolio, which includes genomic and immuno-oncology markers.
It forms part of the company’s extensive NSCLC testing offerings, supporting the adoption of MET-directed treatments and the advancement of precision cancer care.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHeadquartered in the US, NeoGenomics focuses on cancer genetics testing and information services and provides a range of oncology-focused tests.
NeoGenomics medical services vice-president Dr Nathan Montgomery said: 鈥淎ccurate and timely biomarker testing is critical in lung cancer, where targeted therapies can meaningfully change the course of a patient鈥檚 treatment.
鈥淭he c-MET CDx for NSCLC assay adds an important tool to our testing portfolio, helping oncologists quickly identify patients who may benefit from MET-directed therapies. It also complements our PanTracer suite, enabling comprehensive biomarker profiling for NSCLC.鈥�
In October 2024, the company announced the receipt of conditional approval from the New York State Department of Health for two next-generation sequencing (NGS) tests, the Neo Comprehensive Solid Tumor assay and the NeoTYPE DNA & RNA Lung.
